Shattuck Labs, Inc. (STTK) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on June 8, 2026, by Shattuck Labs, Inc., a biopharmaceutical company developing therapies for inflammatory diseases. The filing primarily discloses clinical trial data for its lead candidate, SL-325, and significant capital events regarding warrant exercises.
Key Financial Metrics and Capital Events
The filing does not provide standard financial statements (revenue, profit, cash flow, or debt levels) as it is a current report focused on specific events. However, it discloses the following capital activity:
- Warrant Exercises: On June 9, 2026, the Company received notices to exercise approximately 50.6 million outstanding common stock warrants, representing approximately 96% of warrants issued in an August 2025 private placement.
- Proceeds Received: As of March 31, 2026, the Company had received approximately $5.6 million from the exercise of 5,147,773 warrants.
- Expected Proceeds: The Company expects to receive an additional approximately $49.3 million from the exercise of 45,438,709 warrants.
Material Changes and Clinical Developments
The filing details significant progress in the Company's clinical pipeline:
- SL-325 Phase 1 Data: Released data from a first-in-human, randomized, placebo-controlled trial in 72 healthy volunteers.
- Immunogenicity: Antidrug antibodies (ADA) were detected in only 3.7% (2/54) of participants, with low titers and no impact on pharmacokinetics (PK) or receptor occupancy.
- Pharmacokinetics: Complete DR3 occupancy was observed at doses of 0.1 mg/kg and higher. Inhibition of TL1A binding was durable for over 10 weeks, with modeling suggesting sustainability for greater than 3 months at doses >1 mg/kg.
- Safety: SL-325 was well tolerated with no serious treatment-emergent adverse events. All treatment-related adverse events were Grade 1.
- RECEPTIVE-CD1 Phase 2b Trial: Initiation is expected in the third quarter of 2026. The trial will evaluate SL-325 in moderate-to-severe Crohn's disease with approximately 174 patients. Primary endpoint disclosure is expected in the first half of 2028.
- SL-846 Bispecific: An IND filing for this DR3xIL-23R bispecific antibody is expected in the first half of 2027. Safety and immunogenicity data from toxicology studies are expected in the second half of 2026.
Guidance, Outlook, and Risks
Management outlined the following milestones for 2026 and 2027:
- 2026 Q3: Initiation of the RECEPTIVE-CD1 Phase 2b trial.
- 2026 H2: Expected release of safety and immunogenicity data for SL-846.
- 2027 H1: Expected IND filing for SL-846.
- 2028 H1: Expected disclosure of primary endpoint data for the RECEPTIVE-CD1 trial.
Risks and Contingencies: The filing notes that the press releases and data presentations furnished as exhibits are not deemed "filed" for purposes of Section 18 of the Exchange Act and are not incorporated by reference into other filings, limiting their legal liability scope. The Company relies on the successful progression of clinical trials, which carries inherent risks of failure.
Key Facts for Investor Verification
- Verify the actual receipt of the expected $49.3 million in warrant exercise proceeds and the timing of cash inflows.
- Confirm the initiation date of the RECEPTIVE-CD1 Phase 2b trial in Q3 2026.
- Monitor the upcoming H2 2026 release of SL-846 toxicology data to assess the timeline for the 2027 IND filing.
- Review the full data presentation (Exhibit 99.3) for detailed pharmacokinetic modeling assumptions regarding the 3-month durability of DR3 occupancy.